Venus Remedies receives nod under PLI Scheme
Source: IRIS | 09 Dec, 2021, 01.45PM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 Venus Remedies, a research based pharmaceutical company, has received approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) Scheme for manufacturers of pharmaceutical goods registered in India.
Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme.
As per the scheme, the Company will be eligible for incentive for the financial years 2022-23 to 2027-28, subject to fulfillment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.
Shares of the company gained Rs 27.65, or 5.88%, to trade at Rs 497.70. The total volume of shares traded was 31,750 at the BSE (12.18 p.m, Thursday).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
